Subscribe
shutterstock_1582097611_sundry_photography
Sundry Photography / Shutterstock.com
16 January 2020Big PharmaEdward Pearcey

Former Genentech employee cuts plea deal with FBI in trade secrets case

A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
Trade secrets: an alternative for life sciences IP?
9 July 2020   Amid confusion over patent eligibility, US life sciences IP owners should consider trade secret law when building their IP protection strategy, argues John A Stone of DeCotiis, FitzPatrick, Cole & Giblin.
Big Pharma
Genentech to face revived Hemlibra claims
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
Americas
Ex-DuPont employee gets 42 months over trade secret theft
24 December 2020   A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

article
Trade secrets: an alternative for life sciences IP?
9 July 2020   Amid confusion over patent eligibility, US life sciences IP owners should consider trade secret law when building their IP protection strategy, argues John A Stone of DeCotiis, FitzPatrick, Cole & Giblin.
Big Pharma
Genentech to face revived Hemlibra claims
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
Americas
Ex-DuPont employee gets 42 months over trade secret theft
24 December 2020   A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.

More on this story

article
Trade secrets: an alternative for life sciences IP?
9 July 2020   Amid confusion over patent eligibility, US life sciences IP owners should consider trade secret law when building their IP protection strategy, argues John A Stone of DeCotiis, FitzPatrick, Cole & Giblin.
Big Pharma
Genentech to face revived Hemlibra claims
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
Americas
Ex-DuPont employee gets 42 months over trade secret theft
24 December 2020   A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?